Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy

World Journal of Urology

Volumn 33, Issue 1, 2015, Pages 93-97

  Oh, Daniel S ^a   Koontz, Bridget ^b   Freedland, Stephen J ^a   Gerber, Leah ^a   Patel, Pretesh ^b   Lewis, Stephen ^b   Yoo, David S ^b   Oleson, James ^b   Salama, Joseph K ^b  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biochemical failure; Brachytherapy; Prostate cancer; Statin use

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; AGED; BRACHYTHERAPY; EPIDEMIOLOGY; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; SURVIVAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84896570380     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-014-1281-x     Document Type: Article

References (23)

1. Platz EA et al (2006) Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98(24):1819–1825
2. Murtola TJ et al (2007) Cholesterol-lowering drugs and prostate cancer risk: a population-based case–control study. Cancer Epidemiol Biomark Prev 16(11):2226–2232
3. Poynter JN et al (2005) Statins and the risk of colorectal cancer. N Engl J Med 352(21):2184–2192
4. Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367(19):1792–1802
5. Hamilton RJ et al (2010) Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 116(14):3389–3398
6. Ku JH et al (2011) Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients. Prostate Cancer Prostatic Dis 14(1):63–68
7. Kollmeier MA et al (2011) Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 79(3):713–718
8. Gutt R et al (2010) Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 28(16):2653–2659
9. Soto DE et al (2009) No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. Urology 73(1):158–162
10. Moyad MA et al (2005) Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 66(6):1150–1154
11. Graaf MR et al (2004) Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 30(7):609–641
12. DeClue JE et al (1991) Inhibition of cell growth by lovastatin is independent of ras function. Cancer Res 51(2):712–717
13. Feleszko W et al (1999) Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer 81(4):560–567
14. Matar P et al (1999) Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma. Clin Exp Metastas 17(1):19–25
15. Kusama T et al (2002) 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 122(2):308–317
16. Zhuang L et al (2005) Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 115(4):959–968
17. Rosenthal SA et al (2011) American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 79(2):335–341
18. Scardino P (2005) Update: NCCN prostate cancer clinical practice guidelines. J Natl Compr Cancer Netw 3(Suppl 1):S29–S33
19. Roach M 3rd et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4):965–974
20. Moyad MA et al (2006) Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer. Urol Nurs 26(4):298–303
21. Hamilton RJ et al (2008) The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 100(21):1511–1518
22. Papagikos MA et al (2005) Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)? Brachytherapy 4(4):252–258
23. Kollmeier MA, Stock RG, Stone N (2003) Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 57(3):645–653